Conference abstractPublished 23 Jun 2025

Immune checkpoint blockade plays a crucial role in mounting antitumor immunity thereby improving cancer survival

Authors: Dia Roy

United States

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Immune checkpoint blockade plays a crucial role in mounting antitumor immunity thereby improving cancer survival. Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and cytotoxic lymphocyte T associated protein 4 (CTLA-4) boost antitumor T cell responses and improve survival in patients with cancer1.However, the overall response rate to existing ICI therapies remains low; therefore, the identification of alternative immune checkpoints as therapeutic targets is required. V-domain immunoglobulin suppressor of T cell activation (VISTA) also known as Dies1, Gi24, PD-1H, or DD1α—is a B7 family immune checkpoint protein and a next-generation immunotherapy target2. Previous studies have indicated that VISTA inhibits T cell activation by two modes of action: Firstly, VISTA on the Antigen antigen-presenting cells (APCs) and tumor cells interacts “in-trans” with its cognate receptors on T cells thereby causing T cell suppression. Secondly, VISTA expression can be observed on the T cells itself thereby eliciting “in-cis” intrinsic suppression (Fig 1). Here, we identify leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) as a novel VISTA binding partner, which acts as an inhibitory receptor by interacting with VISTA resulting in T cell receptor signaling suppression3. Mice with T cell-specific LRIG1 deletion developed condescending antitumor responses because of the expansion of tumor-specific cytotoxic T lymphocytes (CTLs) which shows increased effector function and better survival. Sustained tumor control was associated with a reduction of quiescent CTLs (TCF1+ CD62Lhi PD-1low) and a reciprocal increase in progenitor and memory-like CTLs (TCF1+ PD-1+)3. In melanoma patients, elevated LRIG1 expression on tumor infiltrating CD8+ CTLs correlated with resistance to immunotherapies3. These results delineate the role of LRIG1 as an inhibitory immune checkpoint receptor and propose a rationale for targeting the VISTA/LRIG1 axis for cancer immunotherapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Longdom does not store it.

Try:

More from this journal

The newest in Journal of Antivirals & Antiretrovirals.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Antivirals & Antiretrovirals
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Dia Roy”